The effect of mud pack therapy on serum YKL-40 and hsCRP levels in patients with knee osteoarthritis.
The aim of this study was to evaluate the efficacy of treatment with mud pack in knee osteoarthritis (OA) and to determine whether mud pack effects serum levels of YKL-40 and high-sensitivity C-reactive protein (hsCRP) which are reported to be biological markers for articular damage or inflammation in patients with OA. Forty-four patients with the diagnosis of knee OA assigned into two groups were treated with local natural mineral-rich mud pack or hot pack. Treatments were applied for 6 days a week for 2 weeks as a total of 12 sessions. Patients were assessed at baseline, post-treatment, and 3 months after the treatment. VAS, range of motion, 15-m walking time, WOMAC index, Nottingham Health Profile, serum YKL-40, and hsCRP levels were the outcome measures. Pain intensity and joint stiffness decreased in both groups at all follow-ups. Physical activity status was found to persist for 3 months after treatment only in mud pack group. Serum mean YKL-40 and hsCRP levels of the patients were higher compared to healthy control group. Serum YKL-40 level increased significantly only in hot pack group 3 months after the treatment (P < 0.017). No significant change was observed in hsCRP levels in both groups during the whole follow-up periods (P > 0.05). Mud pack and hot pack therapy were both demonstrated to be effective in symptomatic treatment of knee OA until the end of the 2-week treatment period, whereas only mud pack therapy was shown to be effective in functional status over time. In the hot pack group, increased serum YKL-40 level 3 months after the treatment might indicate persistence of cartilage degradation. Maintenance of YKL-40 level in mud pack therapy seems to slow down the progression of knee OA.
Pamukkale University, Denizli, Turkey.
Gonca
G
Güngen
Fusun
F
Ardic
Gülin
G
Fındıkoğlu
Simin
S
Rota
D054392:Adipokines / Q000097:blood*; D000368:Aged; D015415:Biomarkers / Q000097:blood; D001696:Biomechanical Phenomena; D002097:C-Reactive Protein / Q000378:metabolism*; D000071451:Chitinase-3-Like Protein 1; D004185:Disability Evaluation; D018450:Disease Progression; D005080:Exercise Test; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced; D018836:Inflammation Mediators / Q000097:blood*; D007719:Knee Joint / Q000000981:diagnostic imaging / Q000503:physiopathology*; D037102:Lectins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009094:Mud Therapy; D020370:Osteoarthritis, Knee / Q000097:blood / Q000175:diagnosis / Q000276:immunology / Q000503:physiopathology / Q000628:therapy*; D011446:Prospective Studies; D011859:Radiography; D016059:Range of Motion, Articular; D020127:Recovery of Function; D013997:Time Factors; D016896:Treatment Outcome; D014421:Turkey; D016138:Walking
D054392:Adipokines; D015415:Biomarkers; C084533:CHI3L1 protein, human; D000071451:Chitinase-3-Like Protein 1; D018836:Inflammation Mediators; D037102:Lectins; D002097:C-Reactive Protein
Int J Tissue React. 2002;24(2):57-64
12182234
Cell Biochem Funct. 1999 Mar;17(1):29-33
10191506
Rheumatol Int. 2006 Apr;26(6):497-9
16010560
Clin Rheumatol. 2003 Dec;22(6):425-31
14677020
Arthritis Rheum. 2002 Oct;46(10):2613-24
12384919
Joint Bone Spine. 2007 Jan;74(1):60-5
17223602
Ann Rheum Dis. 1990 Sep;49(9):676-81
1700673
Isr J Med Sci. 1997 Apr;33(4):258-61
9347875
Curr Opin Rheumatol. 2003 Sep;15(5):641-6
12960494
Forsch Komplementarmed Klass Naturheilkd. 2000 Oct;7(5):237-41
11096263
Scand J Rheumatol. 1988;17(6):469-74
3266031
Osteoarthritis Cartilage. 2001 May;9(4):289-93
11403034
Rheumatol Int. 2005 Jan;25(1):49-54
14618372
J Altern Complement Med. 2008 Jun;14(5):559-65
18564957
J Clin Invest. 1989 Feb;83(2):585-92
2464001
Rheumatol Int. 2007 Oct;27(12):1157-61
17520260
Scand J Rheumatol. 1999;28(3):171-9
10380840
Ann Rheum Dis. 2005 May;64(5):669-81
15471891
Osteoarthritis Cartilage. 2005 Jan;13(1):28-33
15639634
J Rheumatol. 1997 Aug;24(8):1486-8
9263139
Int J Clin Pharmacol Res. 2005;25(2):77-94
16060398
J Rheumatol. 2001 Feb;28(2):341-5
11246673
Rheumatol Int. 2000;19(3):77-82
10776684
J Clin Rheumatol. 2002 Aug;8(4):197-203
17041359
Ann Rheum Dis. 2004 Feb;63(2):200-5
14722211
Am J Phys Med Rehabil. 2010 Feb;89(2):125-32
19884812
Int J Clin Pharmacol Res. 2000;20(3-4):69-80
11314241
J Rheumatol. 1988 Dec;15(12):1833-40
3068365
Clin Chem. 1998 Mar;44(3):509-16
9510855
Int J Clin Pharmacol Res. 1997;17(4):149-53
9526176
J Biol Chem. 1993 Dec 5;268(34):25803-10
8245017
Osteoarthritis Cartilage. 2002 Aug;10(8):595-601
12479380
Osteoarthritis Cartilage. 2000 Mar;8(2):87-95
10772238
Osteoarthritis Cartilage. 2007 May;15(5):516-23
17157039
Circulation. 2001 Apr 3;103(13):1813-8
11282915
Int J Rehabil Res. 2000 Mar;23(1):31-8
10826123
Int J Pharm. 2003 Mar 6;253(1-2):169-75
12593947
J Investig Med. 1998 Apr;46(4):140-5
9635373
Ann Rheum Dis. 2000 Oct;59(10):828-31
11005786
Br J Rheumatol. 1996 Jun;35(6):553-9
8670576
Curr Rheumatol Rep. 2001 Dec;3(6):535-41
11709117
J Eur Acad Dermatol Venereol. 2000 Sep;14(5):346-8
11305374
Clin Chim Acta. 1997 Dec 10;268(1-2):101-6
9495574
Osteoarthritis Cartilage. 2001 Apr;9(3):203-14
11300743
Ann Rheum Dis. 2001 Jun;60(6):619-26
11350852
Ann Rheum Dis. 1990 Feb;49(2):99-102
2180388